DAVID PENMAN JACOBUS
Medical Practice in Princeton, NJ

5658952, Aug 19, 1997

Aug 29, 1995

8/520822

David Jacobus - Princeton NJ

Jacobus Pharmaceutical Co., Inc. - Princeton NJ

A61K 3117

514598

1-[4-(4'-sulfanilyl)phenyl]urea and its various substituted derivatives can be used to decrease the infectiousness of and reduce the mortality associated with organisms of the genus Leishmania which are responsible for a group of conditions known as Leishmaniasis. This heretofore unrecognized use extends to the known derivatives of ureidodiaminodiphenyl sulfones and includes the novel aryl-ring hydroxylated series of sulfanilylphenylureas of the formula: ##STR1## wherein m and n can be the same or different and may each =0 or 1, R. sup. 1, R. sup. 2, R. sup. 3, R. sup. 4, R. sup. 5, and R. sup. 6 are the same or different and are selected from the group consisting of hydrogen, hydroxyl, halo, C. sub. 1 to C. sub. 6 straight or branch chain alkyl, halo alkyl, polyhalo alkyl, alkoxy, cyano, amino, alkanoylamino, alkoxycarbonylamino, carboxy, alkoxycarbonyl, carbamoyl, acyl, R. sup. 7, and R. sup. 8 are the same or different and are selected from the group consisting of hydrogen, and C. sub. 1 to C. sub.

4046897, Sep 6, 1977

Mar 15, 1976

5/666536

Conrad P. Dorn - Plainfield NJ
Howard Jones - Holmdel NJ
David P. Jacobus - Princeton NJ

Merck & Co., Inc. - Rahway NJ

A61K 3144, C07D21362

424263

5-Mercaptopyridoxine C. sub. 1-4 alkane sulfonates, particularly the ethane-1,2-disulfonate, is a superior pharmaceutically acceptable form of the previously preferred 5-mercaptopyridoxine hydrochloride and hydrobromide.

7563792, Jul 21, 2009

Jun 27, 2007

11/769527

David P. Jacobus - Princeton NJ, US
Guy A. Schiehser - Washington Crossing PA, US
Hong-Ming Shieh - Newtown PA, US
Norman P. Jensen - San Rafael CA, US
Jacek Terpinski - North Brunswick NJ, US

Jacobus Pharmaceutical Company, Inc. - Princeton NJ

C07D 251/10, A61K 31/53, A61P 33/02, A61P 33/08, A61P 31/06

514246, 544204, 544205, 544206, 544207

Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.

2006003, Feb 16, 2006

Jan 27, 2004

10/495553

Dana Giulian - Houston TX, US
David Jacobus - Princeton NJ, US

A61K 31/47, A61K 31/235, A61K 31/195, A61K 31/192, A61K 31/15

514311000, 514562000, 514639000, 514568000, 514532000, 514602000

Combination therapies of substituted quinolines and substituted diphenyl sulfones are disclosed. More specifically, compositions containing substituted quinolines and substituted diphenyl sulfones are disclosed. In addition, methods of using the compositions in the treatment of neurodegenerative disorders, including, inter alia, Alzheimer's dementia, HIV-1 associated dementia, and Creutzfeld-Jakob disease are also disclosed.

4338334, Jul 6, 1982

Feb 29, 1980

6/126045

Norman P. Jensen - New Providence NJ
David P. Jacobus - Princeton NJ
Howard Jones - Holmdel NJ

Merck & Co., Inc. - Rahway NJ

A61K 3116, A61K 3117, A61K 31275, A61K 31655

424322

The invention relates to 1-[4-(4-sulfanilyl)phenyl] urea and derivatives thereof in pharmaceutical compositions and in methods of treating rheumatoid arthritis and immune complex diseases such as dermatitis herpetiformis.

2007012, Jun 7, 2007

Feb 5, 2007

11/671372

Dana Giulian - Houston TX, US
David Jacobus - Princeton NJ, US

A61K 31/195, A61K 31/192, A61K 31/135

514562000, 514646000, 514568000

Combination therapies of substituted quinolines and substituted diphenyl sulfones are disclosed. More specifically, compositions containing substituted quinolines and substituted diphenyl sulfones are disclosed. In addition, methods of using the compositions in the treatment of neurodegenerative disorders, including, inter alia, Alzheimer's dementia, HIV-1 associated dementia, and Creutzfeld-Jakob disease are also disclosed.

4058624, Nov 15, 1977

May 14, 1976

5/686360

David P. Jacobus - Princeton NJ
Eugene L. Dulaney - Summit NJ
Nathaniel Grier - Englewood NJ

Merck & Co., Inc. - Rahway NJ

A01N 902, A01N 920, A01N 922

424330

A composition comprising tris-(hydroxymethyl)aminomethane and diphenyl and loweralkyl substituted diphenyl polyamines, their acid addition salts, and mixtures thereof are useful as antibacterial agents. The composition is particularly useful because of the synergistic improvement obtained against strains of the genus Pseudomonas, as well as other genera.

2010013, Jun 3, 2010

Dec 26, 2007

12/520923

David P. Jacobus - Princeton NJ, US
Guy Alan Schiehser - Washington Crossing PA, US
Kathy Lynne Ales - Princeton NJ, US
Laura Ransom Jacobus - Princeton NJ, US

Jacobus Pharmaceutical Company, Inc. - Princeton NJ

A61K 9/50, A61K 31/606, A61K 9/16, A61P 1/06

424497, 514166, 424400, 424489, 424490, 424494

Methods are disclosed for treating patients suffering from inflammatory bowel disease, including ulcerative colitis or Crohn's disease, by administering an oral or enema dosage form containing at least one aminosalicylate active ingredient. Granular dosage forms and kits are also disclosed.

4069321, Jan 17, 1978

Sep 13, 1976

5/722443

Howard Jones - Holmdel NJ
Shu Shu Yang - Piscataway NJ
David P. Jacobus - Princeton NJ

Merck & Co., Inc. - Rahway NJ

A61K 3159, C07J 900

424236

Novel cholecalciferol and dihydrotachysterol. sub. 3 derivatives produced against metabolic conversions at the 25-position, their preparation, pharmaceutical compositions, methods of treating steroid-induced osteoporosis, senile osteoporosis and secondary hyperparathyroidism, especially that induced by an insufficient amount of calcium in relationship to the amount of phosphate, novel intermediates and their preparation are disclosed.